Abeona Therapeutics narrowed its net loss in Q3 2025 to $5.2 million amid preparation for the ZEVASKYN commercial rollout. Strong early patient demand, broader payer coverage, and increased SG&A spending marked the quarter. The company ended the quarter with $207.5 million in cash and equivalents, supporting operations for over two years.

Abeona posted significant net income in Q2 2025, primarily from the $155M PRV sale, alongside FDA approval and launch preparation for ZEVASKYN.

Abeona Therapeutics Inc. reported a net loss of $12.029 million for the three months ended March 31, 2025, a substantial improvement compared to the $31.578 million net loss for the same period in 2024. This positive change was primarily due to a $7.245 million gain from the change in fair value of warrant and derivative liabilities, contrasting with a $17.301 million loss in the prior year. Operating expenses increased by 38% to $19.727 million, driven by higher research and development and general and administrative costs. The company's cash and cash equivalents stood at $15.936 million, with total assets at $99.364 million.

Abeona Therapeutics reported a net loss of $30.3 million for the third quarter of 2024, which includes a $15.2 million loss resulting from the quarterly remeasurement of the fair value of warrant and derivative liabilities. The company's cash, cash equivalents, short-term investments, and restricted cash totaled $110.0 million as of September 30, 2024, and estimates it is sufficient to fund operations into 2026.

Abeona Therapeutics reported a net income of $7.4 million for the second quarter of 2024, which includes a $24.9 million gain from the remeasurement of warrant liabilities. The company's cash, cash equivalents, short-term investments, and restricted cash totaled $123.0 million as of June 30, 2024. They estimate current resources are sufficient to fund operations into 2026.

Abeona Therapeutics reported a net loss of $31.6 million for Q1 2024. They closed a $75 million underwritten offering in May, extending the expected cash runway into 2026.

Abeona Therapeutics reported its full year 2023 financial results, highlighting a cash position of $52.6 million as of December 31, 2023, and the completion of FDA inspections for its Cleveland manufacturing facility and clinical trial sites related to pz-cel. The company estimates its current resources will fund operations into the first quarter of 2025.

Abeona Therapeutics reported a net loss attributable to common shareholders of $11.8 million for the third quarter of 2023. The company's cash, cash equivalents, restricted cash and short-term investments totaled $54.1 million as of September 30, 2023, which is expected to fund operations into the fourth quarter of 2024. The company completed its first-ever U.S. BLA submission and initiated commercial readiness activities for potential U.S. launch of pz-cel.

Abeona Therapeutics reported license and other revenues of $3.5 million for Q2 2023, compared to $1.0 million in Q2 2022. The company's cash and investments totaled $37.1 million as of June 30, 2023, which, combined with proceeds from a $25 million direct offering, is expected to fund operations into Q4 2024. The company is on track for BLA submission in Q3 2023.

Abeona Therapeutics reported a net loss of $9.1 million for the first quarter of 2023, with license and other revenues at nil, research and development expenses at $8.0 million, and general and administrative expenses at $4.0 million. Cash, cash equivalents, restricted cash and short-term investments totaled $40.7 million as of March 31, 2023, sufficient to fund operations into the third quarter of 2024.

Abeona Therapeutics reported a cash, cash equivalents, restricted cash and short-term investments totaling $52.5 million as of December 31, 2022. They anticipate submitting the BLA for EB-101 to the FDA in late 2Q/early 3Q 2023.

Abeona Therapeutics reported positive topline data from the Phase 3 VIITAL study and is focused on submitting a Biologics License Application for EB-101 to the U.S. FDA. The company is well-funded into the third quarter of 2024.

Abeona Therapeutics reported a net loss of $12.1 million for Q2 2022, with license and other revenues of $1.0 million. The company's cash runway has been extended into Q2 2023 following Ultragenyx assuming financial responsibility for ABO-102 development.

Abeona Therapeutics reported a net loss of $20.8 million for Q1 2022, with license and other revenues of $0.3 million. The company is focusing on its EB-101 pivotal Phase 3 VIITAL™ study and has initiated steps toward regaining compliance with Nasdaq listing requirements.

Abeona Therapeutics reported a net loss of $84.9 million for the full year 2021. The company is focusing on EB-101 and expects topline results in Q3 2022. They also plan to reduce operating expenses and extend cash runway to mid-2023.

Abeona Therapeutics reported its Q3 2021 financial results, with a net loss of $7.0 million. The company is advancing two late-stage pivotal assets and expects to finish patient accrual for the EB-101 Phase 3 VIITAL™ study in Q1 2022, with top-line data readout in Q3 2022.

Abeona Therapeutics reported financial results for the second quarter of 2021, with a net loss of $15.2 million. The company's cash, cash equivalents, and short-term investments totaled $77.6 million as of June 30, 2021. R&D spending was $7.4 million and G&A spending was $5.5 million for the quarter.

Abeona Therapeutics focused on bolstering operational experience, delivering operational excellence, and prioritizing preclinical eye programs. The company appointed a new SVP, Head of Research and Clinical Development, strengthened the Board of Directors, and advanced clinical programs, including EB-101 and ABO-102. Cash, cash equivalents, and short-term investments totaled $86.8 million as of March 31, 2021.

Abeona Therapeutics announced $3.0 million in license and other revenues for the fourth quarter of 2020. Net loss was $15.8 million for the fourth quarter of 2020. Cash, cash equivalents and short-term investments totaled $95.0 million as of December 31, 2020.

Abeona Therapeutics reported license and other revenues of $7.0 million for the third quarter of 2020, compared to zero revenues in the year-ago quarter. Net loss was $7.2 million for the third quarter of 2020, compared to net loss of $17.4 million for the comparable periods in 2019. Cash, cash equivalents, receivables and short-term investments totaled $103.9 million as of September 30, 2020, compared to $129.3 million as of December 31, 2019.

Abeona Therapeutics reported its Q2 2020 financial results, highlighting progress in clinical development, manufacturing, and regulatory affairs. New patients were treated in RDEB and MPS IIIA clinical programs, and internal manufacturing operations resumed in June. General alignment was reached with the CHMP on the path for European marketing authorization application for ABO-102 in MPS IIIA.

Abeona Therapeutics reported first quarter 2020 financial results, highlighting progress in clinical programs and measures taken to mitigate the impact of the COVID-19 pandemic. The company's cash, cash equivalents, and marketable securities totaled $116 million as of March 31, 2020. The net loss was $0.52 per share.

Abeona Therapeutics reported a net loss of $0.30 per share for the fourth quarter of 2019. The company's cash, cash equivalents, and marketable securities totaled $129.3 million as of December 31, 2019, driven primarily by a $103.5 million gross underwritten public offering.